The FDA cites potential cancer risk for the market withdrawal recommendation for Belviq.
- Eisai, which markets the drug in the US, has submitted a request to voluntarily withdraw the drug, the FDA says
- Belviq developer Arena Pharma’s shares are down about 3% after falling as much as 12% on the news
- NOTE: Jan. 14,
FDA Safety Trial Shows Possible Cancer Risk From Eisai’s Belviq
To view the source of this information click
To contact the reporter on this story:
To contact the editor responsible for this story: